CA2289837A1 - Procede et appareil d'administration ciblee de medicament a un patient, mettant en oeuvre une imagerie par resonance magnetique - Google Patents
Procede et appareil d'administration ciblee de medicament a un patient, mettant en oeuvre une imagerie par resonance magnetique Download PDFInfo
- Publication number
- CA2289837A1 CA2289837A1 CA002289837A CA2289837A CA2289837A1 CA 2289837 A1 CA2289837 A1 CA 2289837A1 CA 002289837 A CA002289837 A CA 002289837A CA 2289837 A CA2289837 A CA 2289837A CA 2289837 A1 CA2289837 A1 CA 2289837A1
- Authority
- CA
- Canada
- Prior art keywords
- tissue
- delivery device
- area
- volume
- change
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 100
- 238000002595 magnetic resonance imaging Methods 0.000 title claims description 21
- 238000012377 drug delivery Methods 0.000 title abstract description 77
- 238000012384 transportation and delivery Methods 0.000 claims abstract description 101
- 238000009792 diffusion process Methods 0.000 claims abstract description 76
- 230000005291 magnetic effect Effects 0.000 claims abstract description 36
- 238000009826 distribution Methods 0.000 claims abstract description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 31
- 239000000463 material Substances 0.000 claims description 159
- 239000000126 substance Substances 0.000 claims description 38
- 230000008859 change Effects 0.000 claims description 36
- 239000012530 fluid Substances 0.000 claims description 18
- 239000012528 membrane Substances 0.000 claims description 18
- 230000033001 locomotion Effects 0.000 claims description 16
- 230000004044 response Effects 0.000 claims description 14
- 230000005855 radiation Effects 0.000 claims description 11
- 230000004075 alteration Effects 0.000 claims description 8
- 239000011148 porous material Substances 0.000 claims description 5
- 230000007717 exclusion Effects 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 238000012546 transfer Methods 0.000 claims description 4
- 230000005415 magnetization Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000035515 penetration Effects 0.000 claims description 3
- 230000005540 biological transmission Effects 0.000 claims 2
- 230000002262 irrigation Effects 0.000 claims 2
- 238000003973 irrigation Methods 0.000 claims 2
- 239000004576 sand Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 88
- 229940079593 drug Drugs 0.000 abstract description 86
- 238000003384 imaging method Methods 0.000 abstract description 71
- 210000004556 brain Anatomy 0.000 abstract description 43
- 239000003795 chemical substances by application Substances 0.000 abstract description 42
- 238000007917 intracranial administration Methods 0.000 abstract description 17
- 229940126585 therapeutic drug Drugs 0.000 abstract description 14
- 210000001519 tissue Anatomy 0.000 description 95
- 238000002347 injection Methods 0.000 description 19
- 239000007924 injection Substances 0.000 description 19
- 238000000576 coating method Methods 0.000 description 18
- 230000000694 effects Effects 0.000 description 16
- 210000005013 brain tissue Anatomy 0.000 description 15
- 239000000523 sample Substances 0.000 description 15
- 238000011282 treatment Methods 0.000 description 15
- 239000000243 solution Substances 0.000 description 13
- 238000000502 dialysis Methods 0.000 description 12
- 239000011248 coating agent Substances 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- 239000000853 adhesive Substances 0.000 description 8
- 230000001070 adhesive effect Effects 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 238000001802 infusion Methods 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 8
- 210000000278 spinal cord Anatomy 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 210000001723 extracellular space Anatomy 0.000 description 7
- 238000012800 visualization Methods 0.000 description 7
- 108010083674 Myelin Proteins Proteins 0.000 description 6
- 102000006386 Myelin Proteins Human genes 0.000 description 6
- 230000006399 behavior Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 210000005012 myelin Anatomy 0.000 description 6
- 239000004033 plastic Substances 0.000 description 6
- 229920003023 plastic Polymers 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- -1 proteins Chemical class 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 208000012902 Nervous system disease Diseases 0.000 description 5
- 230000004888 barrier function Effects 0.000 description 5
- 210000004958 brain cell Anatomy 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 5
- 239000002872 contrast media Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 229920002521 macromolecule Polymers 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 239000000700 radioactive tracer Substances 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 208000025966 Neurological disease Diseases 0.000 description 4
- 230000008499 blood brain barrier function Effects 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 210000001218 blood-brain barrier Anatomy 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 239000004020 conductor Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000006073 displacement reaction Methods 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 238000002594 fluoroscopy Methods 0.000 description 4
- 239000000017 hydrogel Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 230000004807 localization Effects 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 210000004126 nerve fiber Anatomy 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 208000003174 Brain Neoplasms Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000004809 Teflon Substances 0.000 description 3
- 229920006362 Teflon® Polymers 0.000 description 3
- 210000003484 anatomy Anatomy 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 210000004289 cerebral ventricle Anatomy 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000004907 flux Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 150000002605 large molecules Chemical class 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 3
- 229910001000 nickel titanium Inorganic materials 0.000 description 3
- 238000012634 optical imaging Methods 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 230000004855 vascular circulation Effects 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000012935 Averaging Methods 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 239000004593 Epoxy Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000012510 hollow fiber Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000013152 interventional procedure Methods 0.000 description 2
- 238000000185 intracerebroventricular administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 2
- 239000002907 paramagnetic material Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 229920002492 poly(sulfone) Polymers 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000002537 thrombolytic effect Effects 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 229910001369 Brass Inorganic materials 0.000 description 1
- 230000005653 Brownian motion process Effects 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000027219 Deficiency disease Diseases 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 108010092674 Enkephalins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000005731 Glucose-6-phosphate isomerase Human genes 0.000 description 1
- 108010070600 Glucose-6-phosphate isomerase Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101001061807 Homo sapiens Rab-like protein 6 Proteins 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 101100537948 Mus musculus Trir gene Proteins 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- 239000004696 Poly ether ether ketone Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 102100029618 Rab-like protein 6 Human genes 0.000 description 1
- 229910052581 Si3N4 Inorganic materials 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000003570 air Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000005098 blood-cerebrospinal fluid barrier Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000476 body water Anatomy 0.000 description 1
- 239000010951 brass Substances 0.000 description 1
- 238000005537 brownian motion Methods 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 210000001736 capillary Anatomy 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000002597 diffusion-weighted imaging Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000003844 drug implant Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003257 excitatory amino acid Substances 0.000 description 1
- 230000002461 excitatory amino acid Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000005294 ferromagnetic effect Effects 0.000 description 1
- 238000002795 fluorescence method Methods 0.000 description 1
- 239000002783 friction material Substances 0.000 description 1
- 239000005350 fused silica glass Substances 0.000 description 1
- 238000011902 gastrointestinal surgery Methods 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 239000013029 homogenous suspension Substances 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000002697 interventional radiology Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 208000001286 intracranial vasospasm Diseases 0.000 description 1
- 239000000797 iron chelating agent Substances 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 230000002139 lathyrogenic effect Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical class C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002324 minimally invasive surgery Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003666 myelinated nerve fiber Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 238000002610 neuroimaging Methods 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000002831 nitrogen free-radicals Chemical class 0.000 description 1
- 239000000615 nonconductor Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 230000008807 pathological lesion Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000007793 ph indicator Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001095 phosphatidyl group Chemical group 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920002530 polyetherether ketone Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229940076788 pyruvate Drugs 0.000 description 1
- 238000011155 quantitative monitoring Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000004627 regenerated cellulose Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- HQVNEWCFYHHQES-UHFFFAOYSA-N silicon nitride Chemical compound N12[Si]34N5[Si]62N3[Si]51N64 HQVNEWCFYHHQES-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 238000000264 spin echo pulse sequence Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 229910001256 stainless steel alloy Inorganic materials 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 238000004326 stimulated echo acquisition mode for imaging Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000002330 subarachnoid space Anatomy 0.000 description 1
- 210000000701 subdural space Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 230000033912 thigmotaxis Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 238000007631 vascular surgery Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000007794 visualization technique Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/48—NMR imaging systems
- G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
- G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
- G01R33/5601—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/005—Devices for introducing or retaining media, e.g. remedies, in cavities of the body for contrast media
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0021—Catheters; Hollow probes characterised by the form of the tubing
- A61M25/0023—Catheters; Hollow probes characterised by the form of the tubing by the form of the lumen, e.g. cross-section, variable diameter
- A61M25/0026—Multi-lumen catheters with stationary elements
- A61M2025/0034—Multi-lumen catheters with stationary elements characterized by elements which are assembled, connected or fused, e.g. splittable tubes, outer sheaths creating lumina or separate cores
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0021—Catheters; Hollow probes characterised by the form of the tubing
- A61M25/0023—Catheters; Hollow probes characterised by the form of the tubing by the form of the lumen, e.g. cross-section, variable diameter
- A61M25/0026—Multi-lumen catheters with stationary elements
- A61M2025/0036—Multi-lumen catheters with stationary elements with more than four lumina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0021—Catheters; Hollow probes characterised by the form of the tubing
- A61M25/0023—Catheters; Hollow probes characterised by the form of the tubing by the form of the lumen, e.g. cross-section, variable diameter
- A61M25/0026—Multi-lumen catheters with stationary elements
- A61M2025/004—Multi-lumen catheters with stationary elements characterized by lumina being arranged circumferentially
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0043—Catheters; Hollow probes characterised by structural features
- A61M2025/0057—Catheters delivering medicament other than through a conventional lumen, e.g. porous walls or hydrogel coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
- A61M25/0068—Static characteristics of the catheter tip, e.g. shape, atraumatic tip, curved tip or tip structure
- A61M2025/0073—Tip designed for influencing the flow or the flow velocity of the fluid, e.g. inserts for twisted or vortex flow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/06—Head
- A61M2210/0693—Brain, cerebrum
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/48—NMR imaging systems
- G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
- G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
- G01R33/563—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution of moving material, e.g. flow contrast angiography
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Radiology & Medical Imaging (AREA)
- Signal Processing (AREA)
- Anesthesiology (AREA)
- High Energy & Nuclear Physics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- General Physics & Mathematics (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Cette invention se rapporte à un appareil et à un procédé d'administration ciblée de médicament à un patient au moyen de l'imagerie par résonance magnétique (IRM). Cet appareil et ce procédé servent à l'administration de médicament à tous types de tissu vivant et font appel à l'imagerie par résonance magnétique pour suivre la trace du médicament administré et estimer la vitesse d'administration du médicament. Un dispositif d'administration de médicament par résonance magnétique visible, positionné au niveau d'un site cible (par exemple, en vue d'une administration intracrânienne) administre au tissu (par exemple, au tissu cérébral) une solution médicamenteuse diagnostique ou thérapeutique. La cinétique de distribution spatiale de l'agent médicamenteux injecté ou infusé fait l'objet d'une surveillance quantitative, non invasive, par IRM à diffusion directionnelle de protons dans l'eau permettant d'évaluer l'efficacité de l'administration du médicament au niveau de l'emplacement cible.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/857,043 US6026316A (en) | 1997-05-15 | 1997-05-15 | Method and apparatus for use with MR imaging |
US08/856,894 | 1997-05-15 | ||
US08/856,894 US6061587A (en) | 1997-05-15 | 1997-05-15 | Method and apparatus for use with MR imaging |
US08/857,043 | 1997-05-15 | ||
PCT/US1998/009942 WO1998052064A1 (fr) | 1997-05-15 | 1998-05-15 | Procede et appareil d'administration ciblee de medicament a un patient, mettant en oeuvre une imagerie par resonance magnetique |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2289837A1 true CA2289837A1 (fr) | 1998-11-19 |
Family
ID=27127382
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002289837A Abandoned CA2289837A1 (fr) | 1997-05-15 | 1998-05-15 | Procede et appareil d'administration ciblee de medicament a un patient, mettant en oeuvre une imagerie par resonance magnetique |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0981761A1 (fr) |
JP (1) | JP2001525703A (fr) |
AU (1) | AU7388398A (fr) |
CA (1) | CA2289837A1 (fr) |
WO (1) | WO1998052064A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11298043B2 (en) | 2016-08-30 | 2022-04-12 | The Regents Of The University Of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
US11497576B2 (en) | 2017-07-17 | 2022-11-15 | Voyager Therapeutics, Inc. | Trajectory array guide system |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6537232B1 (en) * | 1997-05-15 | 2003-03-25 | Regents Of The University Of Minnesota | Intracranial pressure monitoring device and method for use in MR-guided drug delivery |
US6479481B1 (en) * | 1999-06-04 | 2002-11-12 | Ed. Geistlich Soehne Ag Fur Chemische Industrie | Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS) |
SE9902695L (sv) * | 1999-07-14 | 2001-01-15 | Cma Microdialysis Ab | Förbättrad sond |
CA2398967A1 (fr) | 2000-02-01 | 2001-08-09 | Albert C. Lardo | Antenne aiguille transseptale pour irm |
AU2001247806A1 (en) * | 2000-03-24 | 2001-10-08 | Surgi-Vision | Endoluminal mri probe |
FR2823092B1 (fr) | 2001-04-10 | 2004-03-05 | Eurorad 2 6 | Dispositif per-operatoire pour la localisation de tissus marques et procede utilisant un tel dispositif |
GB0110392D0 (en) * | 2001-04-27 | 2001-06-20 | Oxford Instr Plc | Method and apparatus for magnetic resonance imaging |
US8862203B2 (en) * | 2003-03-27 | 2014-10-14 | Boston Scientific Scimed Inc. | Medical device with temperature modulator for use in magnetic resonance imaging |
WO2007064739A2 (fr) * | 2005-11-29 | 2007-06-07 | Surgi-Vision, Inc. | Systèmes de mise en place de dérivation et/ou de localisation guidés par irm et procédés, dispositifs et programmes informatiques associés |
US8790317B2 (en) | 2007-02-13 | 2014-07-29 | Cornell University | Convection enhanced delivery apparatus, method, and application |
US8175677B2 (en) | 2007-06-07 | 2012-05-08 | MRI Interventions, Inc. | MRI-guided medical interventional systems and methods |
US8374677B2 (en) | 2007-06-07 | 2013-02-12 | MRI Interventions, Inc. | MRI-guided medical interventional systems and methods |
US8548569B2 (en) | 2007-09-24 | 2013-10-01 | MRI Interventions, Inc. | Head fixation assemblies for medical procedures |
CA2700531A1 (fr) | 2007-09-24 | 2009-04-02 | Surgivision, Inc. | Plaques compatibles avec l'irm et leur proceder d'utilisation |
US8099150B2 (en) | 2007-09-24 | 2012-01-17 | MRI Interventions, Inc. | MRI-compatible head fixation frame with cooperating head coil apparatus |
US8315689B2 (en) | 2007-09-24 | 2012-11-20 | MRI Interventions, Inc. | MRI surgical systems for real-time visualizations using MRI image data and predefined data of surgical tools |
WO2010040970A2 (fr) * | 2008-10-08 | 2010-04-15 | Renishaw (Ireland) Limited | Cathéter |
EP2211973A2 (fr) * | 2007-10-08 | 2010-08-04 | Renishaw (Ireland) Limited | Cathéter |
WO2009067205A1 (fr) | 2007-11-21 | 2009-05-28 | Surgi-Vision, Inc. | Procédés, systèmes et programmes informatiques pour le positionnement d'un appareil de guidage par rapport à un patient |
ES2854832T3 (es) | 2011-08-01 | 2021-09-23 | Alcyone Lifesciences Inc | Dispositivos microfluídicos de administración de medicamentos |
KR101820534B1 (ko) | 2011-10-07 | 2018-01-22 | 서강대학교산학협력단 | 약물 전달 속도를 정량화하는 방법, 이에 의한 mri 장치 |
US9192446B2 (en) | 2012-09-05 | 2015-11-24 | MRI Interventions, Inc. | Trajectory guide frame for MRI-guided surgeries |
EP2934627B1 (fr) | 2012-12-18 | 2021-04-07 | Alcyone Lifesciences, Inc. | Appareils et procédés permettant d'éviter un reflux dans un système de distribution |
JP2016522069A (ja) | 2013-06-17 | 2016-07-28 | アルキオーネ・ライフサイエンシズ・インコーポレイテッドAlcyone Lifesciences, Inc. | カテーテル先端部を保護する方法および装置ならびにマイクロカテーテル用の定位固定物 |
JP6498670B2 (ja) | 2013-07-31 | 2019-04-10 | アルキオーネ・ライフサイエンシズ・インコーポレイテッドAlcyone Lifesciences, Inc. | 薬剤送達、治療、およびモニタリングのためのシステムおよび方法 |
US10806396B2 (en) | 2015-01-26 | 2020-10-20 | Alcyone Lifesciences, Inc. | Drug delivery methods with tracer |
CN108472019A (zh) | 2016-01-04 | 2018-08-31 | 亚克安娜生命科学有限公司 | 用于治疗中风的方法和装置 |
US10905497B2 (en) | 2017-04-21 | 2021-02-02 | Clearpoint Neuro, Inc. | Surgical navigation systems |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3640269A (en) * | 1969-10-24 | 1972-02-08 | Jose M R Delgado | Fluid-conducting instrument insertable in living organisms |
SE434214B (sv) * | 1982-12-01 | 1984-07-16 | Carl Urban Ungerstedt | Dialysprob, avsedd for inforing i biologiska vevnader |
GB8600665D0 (en) * | 1986-01-13 | 1986-02-19 | Longmore D B | Surgical catheters |
US5154179A (en) * | 1987-07-02 | 1992-10-13 | Medical Magnetics, Inc. | Device construction and method facilitating magnetic resonance imaging of foreign objects in a body |
FI80585C (fi) * | 1988-11-11 | 1990-07-10 | Instrumentarium Oy | Arrangemang foer undersoekning av ett objekt. |
DE4310993A1 (de) * | 1993-04-03 | 1994-10-06 | Philips Patentverwaltung | MR-Abbildungsverfahren und Anordnung zur Durchführung des Verfahrens |
US5470307A (en) * | 1994-03-16 | 1995-11-28 | Lindall; Arnold W. | Catheter system for controllably releasing a therapeutic agent at a remote tissue site |
US5419325A (en) * | 1994-06-23 | 1995-05-30 | General Electric Company | Magnetic resonance (MR) angiography using a faraday catheter |
-
1998
- 1998-05-15 EP EP98921222A patent/EP0981761A1/fr not_active Withdrawn
- 1998-05-15 CA CA002289837A patent/CA2289837A1/fr not_active Abandoned
- 1998-05-15 AU AU73883/98A patent/AU7388398A/en not_active Abandoned
- 1998-05-15 WO PCT/US1998/009942 patent/WO1998052064A1/fr not_active Application Discontinuation
- 1998-05-15 JP JP54956798A patent/JP2001525703A/ja active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11298043B2 (en) | 2016-08-30 | 2022-04-12 | The Regents Of The University Of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
US11298041B2 (en) | 2016-08-30 | 2022-04-12 | The Regents Of The University Of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
US11497576B2 (en) | 2017-07-17 | 2022-11-15 | Voyager Therapeutics, Inc. | Trajectory array guide system |
Also Published As
Publication number | Publication date |
---|---|
WO1998052064A1 (fr) | 1998-11-19 |
JP2001525703A (ja) | 2001-12-11 |
AU7388398A (en) | 1998-12-08 |
EP0981761A1 (fr) | 2000-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6061587A (en) | Method and apparatus for use with MR imaging | |
US6026316A (en) | Method and apparatus for use with MR imaging | |
CA2289837A1 (fr) | Procede et appareil d'administration ciblee de medicament a un patient, mettant en oeuvre une imagerie par resonance magnetique | |
US7505807B1 (en) | Magnetic resonance apparatus for use with active electrode and drug deliver catheter | |
US6272370B1 (en) | MR-visible medical device for neurological interventions using nonlinear magnetic stereotaxis and a method imaging | |
US7048716B1 (en) | MR-compatible devices | |
EP1280456A2 (fr) | Procede et appareil destines a etre utilises avec une electrode active et un catheter d'administration de medicaments | |
US6626902B1 (en) | Multi-probe system | |
CA2505464C (fr) | Localisation de catheter avec information de phase | |
Saito et al. | Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brain | |
US6537232B1 (en) | Intracranial pressure monitoring device and method for use in MR-guided drug delivery | |
JP7503904B2 (ja) | モジュール化された超音波対応人工頭蓋プロテーゼ | |
EP1980201B1 (fr) | Méthode et appareil pour la planification de l'administration locale d'un médicament | |
Blanco et al. | Interventional and intraoperative MRI at low field scanner–a review | |
US20060173283A1 (en) | Method of magnetic resonance imaging | |
BRPI0813640B1 (pt) | Marcador de contraste e método de fabricação de um filamento | |
Blanco Sequeiros et al. | MR-guided interventional procedures: a review | |
Brady et al. | In vivo performance of a microfabricated catheter for intraparenchymal delivery | |
Steiner et al. | Active biplanar MR tracking for biopsies in humans. | |
DE60311142T2 (de) | Verfahren für die magnetische resonanzbildgebung | |
Günther et al. | Interventional magnetic resonance: realistic prospect or wishful thinking? | |
Rothgang et al. | Interventional imaging: MR | |
Hall et al. | Intraoperative magnetic resonance imaging | |
Engler et al. | The effects of magnetic resonance imaging on intravenous infusion devices | |
Yin et al. | Real-time convection delivery of therapeutics to the primate brain |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |